The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Newer treatments, including anti-CD38 monoclonal antibodies and immunomodulating agents, are becoming standard in multiple myeloma management. In patients with relapsed or refractory multiple myeloma, ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

The final draft guidance, released last month, applies to RRMM patients in England and Wales who have received at least three ...

Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, ...

Myeloma UK joined with patients and clinicians to challenge the decision, and today NICE confirmed that Elrexfio will now be ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $250.00.